COPA

DR CRAIG WRIGHT ISSUES SETTLEMENT OFFER TO COPA MEMBERS AND ALL PARTIES IN UPCOMING INTELLECTUAL PROPERTY LITIGATION

Retrieved on: 
Wednesday, January 24, 2024
Bitcoin Core, Bitcoin Cash, High court, Coinbase, Family, Database, Meta, BSV, Mission, ABC, History, COPA, Disability-adjusted life year, BTC, Uniting Church in Australia, White paper, Letter, Charity, Hearing, Cryptocurrency

To that end, today I have sent to my opponents in the COPA litigation (Claim No.

Key Points: 
  • To that end, today I have sent to my opponents in the COPA litigation (Claim No.
  • All parties now have 7 days from the date of this offer to agree this settlement, or we shall progress to trial.
  • Issued by: Dr Craig Wright  All enquiries to: [email protected]
    DR WRIGHT'S OFFER TO SETTLE CLAIMS:
    Claim No.
  • IL-2022-000069 Dr Craig Wright & Another v. BTC Core & Others (Identity Issue only) (together the "Claims")
    1.

DR CRAIG WRIGHT ISSUES SETTLEMENT OFFER TO COPA MEMBERS AND ALL PARTIES IN UPCOMING INTELLECTUAL PROPERTY LITIGATION

Retrieved on: 
Wednesday, January 24, 2024
Bitcoin Core, Bitcoin Cash, High court, Coinbase, Family, Database, Meta, BSV, Mission, ABC, History, COPA, Disability-adjusted life year, BTC, Uniting Church in Australia, White paper, Letter, Charity, Hearing, Cryptocurrency

To that end, today I have sent to my opponents in the COPA litigation (Claim No.

Key Points: 
  • To that end, today I have sent to my opponents in the COPA litigation (Claim No.
  • All parties now have 7 days from the date of this offer to agree this settlement, or we shall progress to trial.
  • Issued by: Dr Craig Wright  All enquiries to: [email protected]
    DR WRIGHT'S OFFER TO SETTLE CLAIMS:
    Claim No.
  • IL-2022-000069 Dr Craig Wright & Another v. BTC Core & Others (Identity Issue only) (together the "Claims")
    1.

Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies

Retrieved on: 
Tuesday, August 15, 2023
Therapy, LR, COPA, USD, Cystic fibrosis, Rare, SGI, Safety, Pharmaceutical industry, Spexy Beast

ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced a capital commitment totaling USD $2.5 million with participation from SPRIM Global Investments (SGI) and institutional investors to fund the upcoming Phase 3 ColiFin® studies, beginning with the COPILOT study which is expected to initiate in the third quarter of 2023. The USD $2.5 million capital commitment will be in the form of USD $1.0 million in secured, interest-bearing debt with partial warrant coverage from SGI and USD $1.5 million subordinated debt mandatorily converting into equity from institutional investors.

Key Points: 
  • 53 LR
    ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced a capital commitment totaling USD $2.5 million with participation from SPRIM Global Investments (SGI) and institutional investors to fund the upcoming Phase 3 ColiFin® studies, beginning with the COPILOT study which is expected to initiate in the third quarter of 2023.
  • The USD $2.5 million capital commitment will be in the form of USD $1.0 million in secured, interest-bearing debt with partial warrant coverage from SGI and USD $1.5 million subordinated debt mandatorily converting into equity from institutional investors.
  • “This additional commitment from SPRIM demonstrates their continued support for the clinical development of ColiFin®, our inhaled macrocycle therapeutic for the management of chronic infections in cystic fibrosis patients” said Jeff Wager, M.D., Chairman & CEO of Spexis.
  • “This new capital allows us to not only initiate the COPILOT study in the third quarter, but will also allow for continued progress across start-up activities for COPA, the second part of our planned pivotal efficacy and safety Phase 3 study.”

Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions

Retrieved on: 
Friday, June 30, 2023
LR, Research, COPA, MD, M & A, Safety, Pharmaceutical industry, Spexy Beast

ALLSCHWIL, Switzerland, June 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it has engaged Maxim Group LLC as a financial advisor to assist in the evaluation of strategic alternatives and fundraising opportunities. Spexis continues to seek additional funding, a strategic transaction or both to advance its ColiFin® Phase 3 program through the planned single pivotal efficacy and safety COPA study following the completion of the COPILOT once-a-day dosing, safety and tolerability clinical trial.

Key Points: 
  • 53 LR
    ALLSCHWIL, Switzerland, June 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it has engaged Maxim Group LLC as a financial advisor to assist in the evaluation of strategic alternatives and fundraising opportunities.
  • Spexis continues to seek additional funding, a strategic transaction or both to advance its ColiFin® Phase 3 program through the planned single pivotal efficacy and safety COPA study following the completion of the COPILOT once-a-day dosing, safety and tolerability clinical trial.
  • Maxim Group LLC is a full-service investment banking firm headquartered in New York with approximately 240 employees.
  • Maxim Group provides a full array of financial services, including investment banking; private wealth management; and global institutional equity, fixed-income, and derivatives sales and trading, as well as equity research.

Berkshire Biomedical Announces Two Poster Presentations at the CPDD 85th Annual Scientific Meeting

Retrieved on: 
Tuesday, June 20, 2023
Communication, Travel, Opioid use disorder, Research, COPA, Berkshire, CO, AIU, Patient, Adherence (medicine), Methadone, Drug development, University of Florida College of Medicine-Jacksonville, Dentition, Safety, Pharmaceutical industry, Office supplies

DALLAS, June 20, 2023 /PRNewswire/ -- Berkshire Biomedical Corporation ("Berkshire" or the "Company"), focused on developing its proprietary drug dispensing technology to enhance patient wellness, announced today that two posters on the Company's Computerized Oral Prescription Administration System (COPA) were presented yesterday at The College on Problems of Drug Development (CPDD) 85th Annual Scientific Meeting, currently being held through Wednesday, June 21, 2023 in Denver, CO. The COPA is a novel, oral liquid dispensing system specifically designed to deliver accurate and precise doses of controlled and non-controlled prescription medications to only an Authenticated Intended User (AIU™), upon confirmation of dual biometric identifications, (fingerprint and dentition), with the goal of enhancing patient wellness and providing remote monitoring.

Key Points: 
  • "The opportunity to present two posters at such an important scientific meeting speaks volumes about the potential technological strength and versatility of our proprietary, cloud-based, healthcare-enabled COPA device," stated John Timberlake, Chief Executive Officer of Berkshire.
  • "COPA may significantly increase the safety and effectiveness of take-home methadone medication administration for opioid use disorder, thus potentially reducing patient burden, improving clinic operational efficiencies, and enhancing patient outcomes.
  • Details of the poster presentations are below:
    Poster Author & Poster Number: John Timberlake, et al (Poster # 3007513)
    Over 500,000 people in the US receive oral liquid methadone to treat opioid use disorder, which, by law, currently is only accessible from federally certified opioid treatment programs.
  • This device may reduce barriers to treatment for methadone patients, improve clinic efficiency, and expand the flexibility of settings for methadone administration.

FTC Policy Director Issues Statement Commending Maine’s Repeal of Certificate of Public Advantage Law

Retrieved on: 
Monday, June 19, 2023
Department, Agriopas, Human services, Policy, Public, Maine Department of Transportation, Goal, COPA, Federal Trade Commission, Patient, Division, FTC, Certification, Paper, Hospital, News, Legislation, Nursing, Facebook

Maine Governor Janet Mills signed the bill on April 24, 2023.

Key Points: 
  • Maine Governor Janet Mills signed the bill on April 24, 2023.
  • In response to this news, the FTC Office of Policy Planning Director Elizabeth Wilkins issued this statement:
    “We are heartened to learn that Maine has repealed its Certificate of Public Advantage law, and that the FTC’s COPA policy paper was influential in this outcome.
  • FTC staff has spent significant time and effort studying the effects of COPAs in healthcare markets.
  • Like the FTC on Facebook, follow us on Twitter, read our blogs, and subscribe to press releases for the latest FTC news and resources.

FTC Policy Director Issues Statement Commending Maine’s Repeal of Certificate of Public Advantage Law

Retrieved on: 
Monday, June 19, 2023
Department, Agriopas, Human services, Policy, Public, Maine Department of Transportation, Goal, COPA, Federal Trade Commission, Patient, Division, FTC, Certification, Paper, Hospital, News, Legislation, Nursing, Facebook

Maine Governor Janet Mills signed the bill on April 24, 2023.

Key Points: 
  • Maine Governor Janet Mills signed the bill on April 24, 2023.
  • In response to this news, the FTC Office of Policy Planning Director Elizabeth Wilkins issued this statement:
    “We are heartened to learn that Maine has repealed its Certificate of Public Advantage law, and that the FTC’s COPA policy paper was influential in this outcome.
  • FTC staff has spent significant time and effort studying the effects of COPAs in healthcare markets.
  • Like the FTC on Facebook, follow us on Twitter, read our blogs, and subscribe to press releases for the latest FTC news and resources.

Spexis provides business update and announces financial results for the full year 2022

Retrieved on: 
Tuesday, May 30, 2023
Partnership, Inhalation, QIDP, Clinical trial, LR, Pharmacokinetics, Research, Bronchiectasis, COPA, BLX, USD, Transplant, Pseudomonas aeruginosa, Plasma, Kidney, Bone marrow, Patient, Collection, Lower respiratory tract infection, Cystic fibrosis, Adolescence, MPV, Mortality, Growth, R, Urinary tract infection, FDA, Letter, CHF, SGI, CF, Safety, Pharmaceutical industry, Spexy Beast

ALLSCHWIL, Switzerland, May 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced its financial results for the full year of 2022 and provided a strategic business update.

Key Points: 
  • Spexis has worldwide rights to ColiFin® ex-Europe and is focused on developing the product first for the U.S. market.
  • Spexis announced positive results from the Phase 1 clinical trial of balixafortide (BLX) in patients with renal impairment in September 2022.
  • In January 2023, Spexis reported promising safety and pharmacokinetics results from a first-in-human study with inhaled murepavadin (iMPV), a novel macrocycle compound.
  • Spexis’ cash position as of December 31, 2022 was CHF 1.8 million (cash and cash equivalents).

FTC Sues to Stop the Potentially Illegal Integration of New Orleans Area Hospitals Over Failure to Follow Federal Reporting Law

Retrieved on: 
Thursday, April 20, 2023
Review, HSR, Hart–Scott–Rodino Antitrust Improvements Act, Lakeview Hospital, General counsel, Obstruction, Tulane Medical Center, Commission, Public, Blog, COPA, Social media, District, The Act, Federal Trade Commission, LCMC, Hospital, District court, Acquisition, Tulane–Lakeside Hospital, Compliance, FTC, HCA, Mergers and acquisitions, HCA Healthcare, Douglas v. U.S. District Court ex rel Talk America, News, Cryptocurrency

"We are seeking to hold LCMC accountable for disregarding the law by ignoring filing requirements and prematurely consummating their deal,” said FTC Chair Lina M. Khan.

Key Points: 
  • "We are seeking to hold LCMC accountable for disregarding the law by ignoring filing requirements and prematurely consummating their deal,” said FTC Chair Lina M. Khan.
  • Despite that, the agency said, LCMC and HCA consummated the transaction on January 3 without ever reporting it to the agencies.
  • The Compliance, Premerger Notification, Office of General Counsel, and Mergers IV divisions were responsible for this matter.
  • For the latest news and resources, follow the FTC on social media, subscribe to press releases and read our blog.

FTC Sues to Stop the Potentially Illegal Integration of New Orleans Area Hospitals Over Failure to Follow Federal Reporting Law

Retrieved on: 
Thursday, April 20, 2023
Review, HSR, Hart–Scott–Rodino Antitrust Improvements Act, Lakeview Hospital, General counsel, Obstruction, Tulane Medical Center, Commission, Public, Blog, COPA, Social media, District, The Act, Federal Trade Commission, LCMC, Hospital, District court, Acquisition, Tulane–Lakeside Hospital, Compliance, FTC, HCA, Mergers and acquisitions, HCA Healthcare, Douglas v. U.S. District Court ex rel Talk America, News, Cryptocurrency

"We are seeking to hold LCMC accountable for disregarding the law by ignoring filing requirements and prematurely consummating their deal,” said FTC Chair Lina M. Khan.

Key Points: 
  • "We are seeking to hold LCMC accountable for disregarding the law by ignoring filing requirements and prematurely consummating their deal,” said FTC Chair Lina M. Khan.
  • Despite that, the agency said, LCMC and HCA consummated the transaction on January 3 without ever reporting it to the agencies.
  • The Compliance, Premerger Notification, Office of General Counsel, and Mergers IV divisions were responsible for this matter.
  • For the latest news and resources, follow the FTC on social media, subscribe to press releases and read our blog.